Guest View
User: Pass: | become a member


Trade of the Day – AZN

Expect AstraZeneca to ride on the coat-tails of Pfizer’s patent victory as they have the #2 product in the sector.

This is a dynamite company anyway with a p/e of just 20 that will be a sector low once the dust clears on PFE and MRK today.

Although I like Merck and Pfizer as well, I think anyone who didn’t buy MRK 2 weeks ago when I recommended it may have missed the bus (or at least the front half).

AZN will make 15% more this year on relatively flat sales, this is something I always like in a company. Also, they are Euro based and get to do all kinds of cool experiments that US companies have to refrain from so I like the pipeline play better.

The Jan $50s are a good buy at under $1.50 (a $1.20 premium) and should be sold with a tight stop once they pass $2. This is a short-term play on the sector but, with PFE gaining 11%, AZN should benefit as well.

Do you know someone who would benefit from this information? We can send your friend a strictly confidential, one-time email telling them about this information. Your privacy and your friend's privacy is your business... no spam! Click here and tell a friend!




You must be logged in to make a comment. Sign up for a membership or log in

Dashboard

 Sector Performances (Today)

 Thermal Imaging